Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091689 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00091689 is a Phase 1 study that has completed, run by Pfizer.
The verdict
NCT00091689, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
Study 1501-852A is a Phase 1 Study with the objective of determining safety and the highest tolerated dose of an immune response modifier cream directly applied to advanced, inoperable, melanoma skin lesions. The study will also measure blood levels of the drug and examine the potential anti-tumor activity of the cream.
Interventions
- DRUG 852A
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-09 |
| Est. Completion | 2006-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00091689
The ClinicalTrials.gov registry entry for NCT00091689 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 852A is the first listed.
NCT00091689 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00091689 about?
NCT00091689 is a clinical study titled "Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions". Study 1501-852A is a Phase 1 Study with the objective of determining safety and the highest tolerated dose of an immune response modifier cream directly applied to advanced, inoperable, melanoma skin lesions. The study will also measure blood levels of the drug and examine the potential anti-tumor a...
What is the current status of trial NCT00091689?
This trial is currently completed. It is a Phase 1 study. The study started on 2004-09. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00091689?
The interventions under investigation include: 852A (DRUG).
Who is sponsoring clinical trial NCT00091689?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.